Decrease (-) Restore Default Increase (+)

Clinical Trials

Topic   Non-Small Cell Lung Cancer
Title   GEODE: Registry of Guardant360® Use and Outcomes in People with Advanced Cancer Including: Module 1: Non-Small Cell Lung Cancer (NSCLC)
Summary   All eligible people for whom blood for a Guardant360 assay has been collected will be invited to participate in the registry. Information on tumor molecular testing, treatment decisions and clinical outcomes from the time of enrollment will be collected in a prospective manner. The registry does not require any specific treatments or procedures but rather collects information on the treatment journey of each participant. Subjects may participate in other clinical studies while also participating in GEODE.
Description   This is a prospective, descriptive registry of people with advanced cancer for whom a Guardant360 assay has been ordered by their health care providers. The registry is divided into modules according to primary cancer diagnosis. Module 1 includes subjects with advanced NSCLC with additional modules added later in the study.
IRB Number   20172566
Inclusion/Notes   To be eligible for this study, patients must meet several criteria, including but not limited to the following: patient must be 18 years of age or older and newly diagnosed with Stage IIIB or IV NSLC or diagnosed with recurrent Stage I-IIIA NSCLC.
Status   Open
Start Date   06/22/2018
Principal Name   Jeffery Schneider, MD
Contact Name   Ying Lin, RN
Email   Ying.Lin@nyulangone.org
Fax   516-663-1871
Current Trial Type   Observation
Phone   516-663-4895
Alternate Phone   516-663-3115